You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

April 2, 2020

Hanoi Issues Further Guidelines on Implementation of COVID-19 Directive

Subscribe to Updates

On March 31, 2020, Vietnam issued Directive No. 16/CT-TTg of the Prime Minister of Vietnam, setting out a wide range of social distancing measures, which we covered in an earlier client alert (click here for details). Following this nationwide announcement, local authorities in various provinces and cities have released their own guidance on implementation of measures for preventing and controlling the COVID-19 outbreak.

The Chairperson of the People’s Committee of Hanoi (“Hanoi PC”) issued Directive No. 05/CT-UBND, under which, in addition to the application of measures as required by the Prime Minster, the Chairperson of the Hanoi PC also further detailed which businesses are considered “essential” and therefore not subject to suspension. For those operating within the jurisdiction of the Hanoi PC, the following businesses are considered “essential”:

  • General supermarkets (except for entertainment and on-site dining services); shopping malls (including general supermarkets and hospitals operating in such shopping malls); street markets (including stalls for food, fruit, vegetables, and dried food); convenience stores and mini supermarkets (except for on-site dining services); grocery stores selling fruit; tourist accommodation premises; chain stores selling agricultural products or medicines; health care services; postal services; banking and electronic payment services; television and telecommunications services; security services; petrol, gas, and oil sellers; funeral services, cemeteries, cremation services, detoxification facilities, and social protection facilities.
  • Production and trading of essential goods including production, preliminary processing, and processing of food, fruit, pharmaceuticals, medicines, medical equipment and supplies for epidemic prevention and control and national security purposes; services of electricity and water supply and environmental sanitation, livestock and poultry farms, aquaculture, clean water supply plants, factories for manufacturing medical masks, factories producing bottled water and juice, and factories and enterprises that are producing under contracts under which products must be delivered before April 15, 2020. Other than these permissible establishments, other factories, production units and construction sites are required to be closed and the employees must be off work.

Notably, neither the directive of the Prime Minister nor the directive from Hanoi specifically mention other service providers such as tax, auditing, notarial offices, etc. It appears that those service providers are allowed to continue operating based on public statements made in interviews by Mr. Mai Tien Dung, Minister and Chairman of the Government Office. However, the operation of those entities may be changed following a shift in circumstances.

Guidance for Ho Chi Minh City, Binh Duong Province and other localities has also been issued and the guidelines may differ from locality to locality. If you have any questions or concerns, please reach out to us at [email protected] for our further assistance.

Related Professionals

Industries

Aviation

Energy

Insurance

Life Sciences

Technology

Practices

Antitrust and Competition

Banking and Finance

Compliance and Investigations

Corporate/M&A

Customs and International Trade

Dispute Resolution and Litigation

Employment

Intellectual Property

Real Estate

Regulatory Affairs

Tax

Location

RELATED INSIGHTS​ 

July 16, 2025
On June 27, 2025, the National Assembly of Vietnam officially passed the amended Law on Atomic Energy, which will take effect on January 1, 2026. This legislative milestone follows the release of the fourth draft in June 2025, which was circulated for public consultation and builds upon earlier drafts from February, April, and early June. (See our previous article on the draft version here), Many provisions have been retained or refined to ensure greater specificity and alignment with Vietnam’s current legal framework. Once in force, the amended law will replace the 2008 Law on Atomic Energy (No. 18/2008/QH12), marking a significant step forward in modernizing Vietnam’s legal infrastructure for nuclear energy. The new law aims to harmonize with international standards, promote the safe and sustainable development of nuclear power, and facilitate future nuclear projects in the country. Noteworthy Updates in the Final Legislation Definition of National Radiation and Nuclear Safety Authority (NRNSA): The law introduces a clear definition of the NRNSA, outlining its roles and responsibilities in line with IAEA standards. Currently, this function is performed by the Vietnam Agency for Radiation and Nuclear Safety (VARANS) under the Ministry of Science and Technology. Digital Transformation Requirements: New provisions mandate the development of an integrated digital platform for data management, administrative procedures, and safety oversight, enhancing transparency and security. Policy Support for Training and Privatization: The law sets out principles for workforce incentives and sector privatization, with detailed regulations to be issued by the government. Dedicated Safety and Security Mechanism: A new section outlines inspection, supervision, violation handling, and enforcement procedures in the field of atomic energy, particularly for nuclear power plants. The NRNSA is empowered to conduct unscheduled inspections, suspend operations, and recommend license revocation when safety risks are identified. Key Provisions Retained or Clarified from the Draft Licensing
Read More
July 15, 2025
On July 1, 2025, Vietnam’s Ministry of Health issued Circular No. 30/2025/TT-BYT providing updated guidance on the application of drug quality standards, testing of drugs and pharmaceutical ingredients, and procedures for the recall and handling of noncompliant drugs (Circular 30). Circular 30 officially came into effect on the same day and replaces Circular No. 11/2018/TT-BYT and its amendments. Key highlights of Circular 30 are presented below. Drug and Pharmaceutical Ingredient Quality Standards Circular 30 maintains consistency with previous regulations regarding the selection of an applicable quality specification. Pharmaceutical businesses and drug preparation establishments may still choose to apply standards from the Vietnamese Pharmacopoeia, reference pharmacopoeias (including the United States Pharmacopoeia, the European Pharmacopoeia, the British Pharmacopoeia, the Japanese Pharmacopoeia, and the International Pharmacopoeia), or an in-house specification. Priority is given to the Vietnamese Pharmacopoeia and reference pharmacopoeias, encompassing quality indicators, quality levels, and testing methods. If alternative pharmacopoeias or in-house specifications are used, they must meet the requirements outlined in the corresponding monographs of the Vietnamese or reference pharmacopoeias. At the time of registration, the quality standards of drugs and pharmaceutical ingredients must comply with either the current version of the pharmacopoeia or a previous version of the pharmacopoeia that is no more than two years older than the current version. The requirement for updating quality specifications in line with the quality under the corresponding pharmacopoeia also applies to products that have already been granted marketing authorization. Testing Drugs and Pharmaceutical Ingredients in Quality Management Similar to the regulations under the previous circular, if pharmaceutical businesses disagree with the sample testing results, they may, within five working days of receiving the test report, request that the state quality inspection authority designate an alternative testing facility. The testing period for establishments listed as foreign drug manufacturers with quality violations remains
Read More
July 15, 2025
Thailand has established new safe harbor rules that require social media platforms to remove specified content within 24 hours of government notification. On July 5, 2025, the Notification of the Electronic Transactions Commission on Measures to Prevent Technological Crimes for Social Media Service Providers was issued and took effect. This followed a hearing in May 2025 where only a select group of social media and online communication platform operators were invited to attend and comment on draft rules that could exempt social media platform operators from joint liability under the amended Emergency Decree on Measures for the Prevention and Suppression of Technological Crimes in cases involving victims of technological crimes. Safe Harbor Rules The notification stipulates procedures that must be followed in order to receive the protection of the safe harbor rules. Upon being notified by the Division of Prevention and Suppression of Cybercrime, Office of the Permanent Secretary of the Ministry of Digital Economy and Society (MDES) of the presence of false or misleading information that may lead to the commission of a technological crime, social media service providers must immediately take down the specified content, with a maximum allowable turnaround time of 24 hours from the time of receiving the notification. Social media service providers are required to promptly report the outcome of each takedown to the MDES Division of Prevention and Suppression. This shift in Thailand’s regulatory approach to social media content moderation establishes clear government oversight mechanisms while providing platforms with liability protection for compliance. As the new rules took immediate effect, social media platforms need to ensure that they have adequate systems and processes in place to comply with the requirements.
Read More
July 14, 2025
Life sciences specialists from Tilleke & Gibbins have updated the firm’s guide to pharmaceutical data exclusivity regulations and practices in Southeast Asia. This guide contains quick-reference information on the availability of data exclusivity protections and limitations in Cambodia, Indonesia, Laos, Malaysia, Myanmar, Thailand, and Vietnam. Developing and launching a new drug on a commercial scale requires an enormous amount of time and investment in research and development (R&D), including pre-clinical testing and clinical trials. When considering the aggregate amount of drug development costs, it is important to recognize that this includes not only the investment in developing new drugs that get approved by a government food and drug regulator and are successfully brought to market, but also the R&D expenditures on a large number of potential pharmaceutical compounds and products that never actually make it to market. In particular, considerable investment is required in order to conduct and produce clinical trial data—to prove safety, efficacy and effectiveness of a new drug—that would warrant marketing approval by the regulatory authority. Such data is proprietary in nature and highly valuable for a research-based pharmaceutical company that develops an original drug. On the other hand, patent law typically confers generic drug manufacturers with the ability to engage in various preparatory activities with a view to obtaining marketing approval for a generic product before the patent for the original drug expires (commonly known as a “Bolar provision”). Since a generic drug maker may submit an application for marketing approval of a generic product before the relevant patent expires, the extent to which the drug originator’s data submitted to the regulatory authority is protected—or in other words, the extent to which the generic company may rely on the drug originator’s previously filed data, which underpins the safety and efficacy of the drug, to support
Read More